Fulvestrant

目录号:S1191 别名: ICI-182780, ZD 9238

Fulvestrant Chemical Structure

Molecular Weight(MW): 606.77

Fulvestrant是一种Estrogen receptor(ER)拮抗剂, 无细胞试验中IC50为0.094 nM。

规格 价格 库存 购买数量  
RMB 533.25 现货
RMB 567.34 现货
RMB 2233.34 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的6个实验数据:

  • PTPH1 confers breast cancer cell sensitivity to fulvestrant. E and F, PTPH1 overexpression increases the growth inhibition by fulvestrant. PTPH1 was overexpressed by a Tet-on system or a stable transfection, and resultant cells were incubated with fulvestrant as indicated for about 2 weeks. Colony formed was stained and counted. Results shown are normalized to its own solvent control of Vector and PTPH1-overexpressed cells, respectively (means ± SD; n = 3–5) with insets showing PTPH1 overexpression. *, versus vector or no Tet cells for E and F.

    Mol Cancer Ther 2014 13(1), 230-8. Fulvestrant purchased from Selleck.

    Biochim Biophys Acta, 2018, 1863(6):625-638. Fulvestrant purchased from Selleck.

  •  

    Fulvestrant resistance induced by 6 different ZF-TFs. (A) Drug sensitivity of fulvestrant-selected MCF7 ZF-TF-transduced cells. MCF7 cells transduced with one of six different ZF-TF-expressing retroviruses selected first in puromycin (the transduction selection marker) and then in fulvestrant for 1 month were grown in the absence of fulvestrant for 7 days and then challenged with 100 nM fulvestrant or vehicle (0.1% ethanol) for 21 days followed by crystal violet staining and visualization. Data are representative of triplicate experiments.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

    Fulvestrant resistance induced by 6 different ZF-TFs. (B and C) Growth curves of MCF7 and T47D cells in the presence and absence of fulvestrant. Comparison of cell growth rates (cell number, mean +/2 SEM, n = 8; time in days as indicated) of MCF7 and T47D cells stably transduced with control retrovirus or one of six different ZF-TF-expressing retroviruses (7, 19, 64, 70, 83 and 115) in the presence (blue line) or absence (pink line) of fulvestrant.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

  • CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments. (c) MCF-7 and MR cells were treated with different concentrations of ICI, collected after 24 h and then immunoblotted with the indicated antibodies.

    Oncogene, 2017, 36(16):2255-2264. Fulvestrant purchased from Selleck.

    A: Time dependent loss of MGMT activity in ERα-positive MCF7 and T47D tumor cells but not in ERα-negative MDAMB-468 cells after 1 μmol/L Fulvestrant treatment (upper panel). Concentration dependent inhibition of MGMT activity in MCF7 and T47D cells but not in MDA-MB-468 cells after a 72 hours exposure to fulvestrant (lower panel). The data represents the mean of two independent experiments in duplicate and the last time point (72 hours) as assessed by student's t-test was significant at P < 0.05. B: Decreased MGMT and ER-α protein levels in MCF7 cells after 48 hours and 72 hours fulvestrant exposure. ICI is fulvestrant, also called ICI-182,780. C: Decreased MGMT and ER-α protein levels in T47D cells after 48 hours and 72 hours fulvestrant exposure.

    J Biomed Res, 2016, 30(5):393-410. Fulvestrant purchased from Selleck.

产品安全说明书

Estrogen/progestogen Receptor抑制剂选择性比较

生物活性

产品描述 Fulvestrant是一种Estrogen receptor(ER)拮抗剂, 无细胞试验中IC50为0.094 nM。
靶点
ER [1]
(Cell-free assay)
0.94 nM
体外研究

Fulvestrant 有效抑制ER阳性的MCF-7生长(IC50为 0.29 nM),而对ER阴性的的 BT-20人类乳腺癌细胞的生长没有作用效果。Fulvestrant 使细胞在 G0/G1 期累积,也降低了能持续进行DNA合成的细胞比例。[1] Fulvestrant 竞争性地抑制雌二醇与雌激素受体结合。 Fulvestrant通过损害受体二聚化和能量依赖型核质转运,而阻断ER的核定位。由于Fulvestrant-ER复合体的不稳定性,Fulvestrant与ER的结合最终会导致 ER蛋白的加速退化。[2] Fulvestrant (10 nM) 不仅可降低IGF-IR mRNA水平,也降低半衰期。[3] 100 μM Fulvestrant 处理MCF-7细胞,提高TNFR1 和TRADD 稳态的mRNA水平,这种作用具有时间依赖性。[4] Fulvestrant 作用于LNCaP人类前列腺癌细胞,可以下调雄激素受体的表达,也减少雄激素的反应。Fulvestrant也显著降低R1881 刺激的生长,降低 70%。[5]Fulvestrant作用于未成熟的小脑神经元,通过快速激活MAPK,可以调节有丝分裂和细胞死亡。[6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 M3W1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7MUWpYOS5|LUGwNFAhdk1? MYO0PEBp M{S0cIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmDWNlQ6Pzl{OUS=
MCF-7/LTED MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K5[FEvOy1zMECwJI5O MoC5OFghcA>? NF71RotqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGDrToIzPDl5OUK5OC=>
HCC1428 M2f6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXexMlMuOTByMDDuUS=> NXLmVohQPDhiaB?= MYXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NF7vdnkzPDl5OUK5OC=>
HCC1428/LTED M130PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zieVEvOy1zMECwJI5O NH;Ub4s1QCCq MmXjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2LqR|I1QTd7Mkm0
LCC1 MmW5SpVv[3Srb36gRZN{[Xl? MWixNFAhdk1? MYe0PE0yPDRiaB?= NITNSmpi[3SrdnH0[ZMhXVCUIIPp[45idGmwZx?= MonBNlQ5PTh{N{e=
LCC9 M3WyWGZ2dmO2aX;uJGF{e2G7 MmrGNVAxKG6P NHLKe481QC1zNESgbC=> MWThZ5RqfmG2ZYOgWXBTKHOrZ37hcIlv\w>? MoC5NlQ5PTh{N{e=
MCF-7  M3X4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCxNFAhdk1? MUK1JIQ> M1vCSolvcGmkaYTzJINmdGxiZ4Lve5RpKHSxIEGw89yG NXPpdmVDOjR6MUm1OVA>
mesangial  M{njNWZ2dmO2aX;uJGF{e2G7 NYnzNnZJOC5zLUGwNEBvVQ>? NF;5WZo1QCCq MX3zeZBxemW|c3XzJHRITi4QskGtbY5lfWOnZDD0fZBmKEmYIHPvcIxi\2Ww M1HXZ|I1Pzl|NkO5
Mesangial M2PafGZ2dmO2aX;uJGF{e2G7 MnTONE4yNTFyMDDuUS=> Ml\aNE42KGh? M3PU[YlvcGmkaYTzJHRITi4QskGtbY5lfWOnZDDTcYFlOiCyaH;zdIhwenmuYYTpc44hfmmjIFfQSXI> M1H5dFI1Pzl|NkO5
ER+ MCF-7/2a NUG1[JpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEC0JO69VQ>? MlW5NVU{OjR6OES=
ER+ MCF-7 NUO2T3dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\ycJAzODBiaB?= NWrhN21IUUN3ME2wMlIyKG6P M{H6cFE2OzJ2OEi0
MCF-7  NWPFWo5pTnWwY4Tpc44hSXO|YYm= Mm\0NVDDqG6PwrC= NEixeGs4OiCq MX3y[ZZmenOnczD0bIUh\XO2cn;n[Y4h\W[oZXP0LGlEPTBiMT65JOOYKDFy4pkSPUBOMQ>? NGr4XY4zPDlyOE[1Ni=>
MCF-7  M{S5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPW[41KSzVywrDv[kBieHC{b4jpcYF1\Wy7IEKgcm0> MYmyN|Q1QDN2Nh?=
H1975  MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTZSZQ{yqEQvF2= MmPENUBu NHzOWWRqdmO{ZXHz[ZMhfGinIHfl[ol1cW6rYjDz[Y5{cXSrdnn0fUBw\iCKMUm3OUBk\Wyuc9Mg NHXhXIYzPDJ4OEixNC=>
H1975 NV;RcoRHTnWwY4Tpc44hSXO|YYm= MYSzxsDPxE1? NVvZdVNiOSCv NVnPPIFVfXC{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJGxmfC15Yx?= M2WybVI1OjZ6OEGw
MCF-7  M2nKR2Z2dmO2aX;uJGF{e2G7 NGT6UGsyODEkgJnuUeKh MXO3NkBp NWDYTVBoemW4ZYLz[ZMhfGinIIDyc5Rm[3SrdnWg[YZn\WO2IH;mJGUzyqCrbjDj[YxtKGmwdnHzbY9v M{XOTlI{QTN4N{ez
MCF-7  NYXoR3d1TnWwY4Tpc44hSXO|YYm= NXrQ[GlGOTBy4pEJcm3DqA>? NFn5SWEzPC92ODDo MlrU[oFkcWyrdHH0[ZMhcW64YYPpc44hfGi{b4XnbEBOVVC|JzDtc4R2dGG2aX;u NWjpWXp4OjN7M{[3O|M>
BT474-tet-shMED1 MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHnNE4yNTVizszN NVrOVGtCPyCm MWnpcoNz\WG|ZYOgL2RwgCCrbnT1Z4VlKGOnbHyg[IVifGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NF7nNXUzOzl|NkKzOC=>
ZR75-1-tet-shMED1  M4P1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTFeIFpOC5zLUWg{txO NY\2bFNsPyCm MnrxbY5kemWjc3XzJEtFd3hiaX7keYNm\CClZXzsJIRm[XSqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NI\zXHkzOzl|NkKzOC=>
MCF-7-tet-shMED1 M3\2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\3[JV{OC5zLUWg{txO MXy3JIQ> NXO3WmtrcW6lcnXhd4V{KCuGb4igbY5lfWOnZDDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M{\UZ|I{QTN4MkO0
HepG2  M3v5[mZ2dmO2aX;uJGF{e2G7 NEC0VXMxNjBzLUGwJO69VQ>? MX6xPEBpyqB? NGnHXJRi[3SrdnH0[ZMhfGinIFXSSU1u\WSrYYTl[EB1emGwc3PybZB1cW:wIH;mJGFHOkWU NFvjfnkzOzd|M{G4PC=>
MCF-7L  M3SyUmZ2dmO2aX;uJGF{e2G7 MYixNFAhdk4EoB?= NUf4dnVFOTBibXnuM|I1KGhxNEigbC=> M3\iWpJme3WudIOgbY4hTUeIUjygTGVTOiCjbnSgTGVTOyCyaH;zdIhwenmuYYTpc44h[XRicILvcI9v\2WmIHX4dI9{fXKn NXqwPZVROjN4OE[0NVY>
MCF-7L  NXTSSllMTnWwY4Tpc44hSXO|YYm= NFHX[20yODBibl5CpC=> MnHLOFghcA>? M3X4Z4lv\HWlZYOgeZBz\We3bHH0bY9vKG:oIH3SUmEhd2ZiRVfGVkBtcWejbnSgTGIuTUeI NVXzcGhZOjN4OE[0NVY>
MCF-7L NIPkO4FHfW6ldHnvckBCe3OjeR?= NVO3eWJIOTByIH7NxsA> MnPiOFghcA>? MXzpcoR2[2W|IFXHSnIh\mGvaXz5JI1mdWKncjDhZ5RqfmG2aX;uJJJmeXWrcnXkJGVT M2j4O|I{Pjh4NEG2
C4-12  NVTzfG9KTnWwY4Tpc44hSXO|YYm= M{i0O|ExOCCwTdMg MVG0PEBp M3SyTolv\HWlZYOgSWdHWiCoYX3pcJkhdWWvYnXyJIFkfGm4YYTpc44hemWzdXny[YQhTVJ? NF3Te4wzOzZ6NkSxOi=>
MCF-7L MUDGeY5kfGmxbjDBd5NigQ>? NIPZeJUyODBibl5CpC=> NFfKcGozPCCq M3nHXolv\HWlZYOgSWdHWiCyaH;zdIhwenmuYYTpc44hemWzdXny[YQhUEJvRVfGJIZ2dmO2aX;u Mnf2NlM3QDZ2MU[=
MMQ  MX\GeY5kfGmxbjDBd5NigQ>? NXPCeYdTOC14MkWgcm0> M37iRVczKGh? MVPkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCnc4Tyc4dmdiC{ZXPldJRwei4QsTCoSXLPuSl? NHXHU4szOzV{M{O1Oy=>
H1975  NWnTW|k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3qxZlAvOzF{NT2xNEDPxE1? NGXSc2E3KGR? M3y4dYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MX6yN|M6QTl3Nx?=
H1975  MWPBdI9xfG:|aYOgRZN{[Xl? NWC2WZVoOjByIH7N NHvyOY04OiCq M{TjWoVvcGGwY3XzJIVzdG:2aX7pZkBqdmS3Y3XkJIFxd3C2b4Ppdy=> NVLyNGdKOjN|OUm5OVc>
MCF-7  NFHEcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfhSHFmOTBxMUCwM|ExODBibl2= M3;xWFIwPC94IHS= MXfEUXNQ MVvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLTDk[ZBmdmSnboSgcYFvdmW{ MnvnNlM{OTN3ME[=
MCF-7  M{XBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6xNFAhdk1? MYS0JIQ> M17nc2ROW09? NIjjXFZqdmS3Y3XzJIEhcGmpaHXyJJBzd3CxcoTpc44hd2ZiY3XscJMhcW5idHjlJGcyKHCqYYPlxsA> NVHrZXo5OjN|MUO1NFY>
MLO-Y4  MYPGeY5kfGmxbjDBd5NigQ>? M2XzNlHDqM7:TR?= M4nsdVEhcA>? NInBe45qdmirYnn0d{BGOi2rbnT1Z4VlKEO6NEOg[ZhxemW|c3nvci=> MmTNNlMzPDdyNUe=
MCF-7 NIXJUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjmNVAxKG6P MXW0PEBp MUHhZpJw\2G2ZYOgeIhmKHC{b3zp[oVz[XSrdnWg[YZn\WO2IH;mJI1w\GW{YYTlJI5qfHKxc3H0bZZmKHO2cnXzdy=> NHXmNHgzOzJzNke0OC=>
TG1-1  Moi4SpVv[3Srb36gRZN{[Xl? MoHxNeKh|ryP MUGyOEBp M2fw[YFjem:pYYTld{BGOsLiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhUEmILUJOtS=> Mmf5NlMxQDh4MEe=
TG1-1  NWDkSWZlTnWwY4Tpc44hSXO|YYm= NICwPWoyyqEQvF2= MV2yOEBp M3;KOoFjem:pYYTld{BGOsLiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhWEl|Sx?= M4C1NlI{ODh6NkC3
MCF7 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rDcVExOCCwTR?= MV[0PEBp NYOyXnpRdGWjZIOgeI8h[SC|aX3pcIFzKGyxc4OgbY4he3W{dnn2ZYwh[XNid3n0bEBld3ixcoXibYNqdiCjbH;u[S=> NILUSHQzOzB5N{K0PS=>
MCF7 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYixNFAhdk1? NWDzblJXPDhiaB?= MkXB[Y5p[W6lZYOgcpV1dGmwLX3l[IlifGWmIHPlcIwh\GWjdHi= M3z6OlI{ODd5MkS5
MCF-7  M1zpV2Z2dmO2aX;uJGF{e2G7 M4j0eVYhcA>? M2jITWROW09? NV;rVFRS[XS2ZX71ZZRmeyC2aHWg[ox2\GmxeH;ubYwuKG:{IH\lcohmgGGvaXStbY5lfWOnZDDpcoNz\WG|ZTDpckBucVJvMkGg[ZhxemW|c3nvci=> MknTNlMxPTJyM{[=
MCF-7 M2WzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvHNJJwOTByIH7NM|Eh|ryP M2HqUlUh\A>? NV3XSnh2cW6qaXLpeJMhfGinIIP0bY12dGG2aX;uJI9nKDF5zsKt[ZN1emGmaX;s NHzNfVczOjl6Mke2OS=>
MCF-7 M3H2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLjRpgyODBibl2= MX21JIQ> NIjzZXRqdmirYnn0d{B1cGVic4TpcZVt[XSrb36gc4Yh\nW|YYLp[YxqdiCK NVm2S4s1OjJ7OEK3OlU>
1471.1 MkDCSpVv[3Srb36gRZN{[Xl? NXTIfZRMOTByIH7N NIPib5YyKGh? M1LYSWV1V0kEoB?= NGXT[HN1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> NYHQU3gyOjJ6NkmxNFY>
MCF-7 NVjMUVhFTnWwY4Tpc44hSXO|YYm= Mlf0NVAxKG6P NXnGeppOOSCq M{HTc2V1V0kEoB?= MWL0ZYtmeyCxbjDhJJB2dmO2YYTlJJN1[WmwaX7nJJBifHSncn6= NXKzWXFPOjJ6NkmxNFY>
HeLa NWTtepZmTnWwY4Tpc44hSXO|YYm= NUnvU2pQOTByIH7N MmixNUBp M1Tv[WV1V0kEoB?= Mn3teIFs\XNib36gZUBxfW6ldHH0[UB{fGGrbnnu[{Bx[XS2ZYLu NEPFfGkzOjh4OUGwOi=>
COS-7  NFHZZlFHfW6ldHnvckBCe3OjeR?= MX2xNFAhdk1? NGH2cXcyKGh? NGTtcGRGfE:KwrC= NGP2fHR1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> NFHSR5czOjh4OUGwOi=>
BG1L-OHTLT  MUXGeY5kfGmxbjDBd5NigQ>? NILWfGsyOMLibl2= M2O0fVI1yqCqwrC= MVjpcohq[mm2czDFVu6yKGW6cILld5Nqd25? NF;6NVczOjZ3MkW1PC=>
BG1L-ICILT NH3keFRHfW6ldHnvckBCe3OjeR?= MUKxNOKhdk1? NX[xXFJOOjUEoHlCpC=> NFXncGVqdmirYnn0d{BGWs7zIHX4dJJme3Orb36= NVz0bWtrOjJ4NUK1OVg>
PC-9 MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSwMlAxOy1|MDFOwG0> NY[4WFlkPDhiaB?= NYLodHl3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYK3Um53OjJ3NkC2N|Q>
H1650 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDaUGpVOC5yMEOtN|Ah|ryP MYq0PEBp MoHGbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NH\6dJYzOjV4ME[zOC=>
H1975 NFnsfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGCzUGsxNjByMz2zNEDPxE1? M{fkRlQ5KGh? NIe4TY5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIT5TXUzOjV4ME[zOC=>
H1975 MoHISpVv[3Srb36gRZN{[Xl? M2L4W|PDqM7:TR?= NGrMfpY{KGh? MXXhZpJw\2G2ZYOgeIhmKHCqb4PwbI8uTUeIUjDpcoR2[3Srb36gZpkh\XO2cn;n[Y4> NX22cY5MOjJ3NkC2N|Q>
H1975 M3fyTGZ2dmO2aX;uJGF{e2G7 NEHlUog{yqEQvF2= MofaO{Bl M37YT4lv\HWlZYOgSWdHWiCneIDy[ZN{cW:w MXyyNlU3ODZ|NB?=
HTR-8 MUDGeY5kfGmxbjDBd5NigQ>? NWPCVYdTOcLizszN MVixMVQ5KGh? M4LwUYRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFnHSmJRPyCvUl7B MXiyNlM5OzFzMR?=
JEG-3 MlfISpVv[3Srb36gRZN{[Xl? Mn7hNeKh|ryP NX\He2FnOS12ODDo M4TTVIRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFnHSmJRPyCvUl7B M3[0WlIzOzh|MUGx
Huh7 M2DiSWZ2dmO2aX;uJGF{e2G7 MnvVOVDDqM7:TR?= MVy0PEBp NHPJbpRqdmirYnn0d{Bo\W6rc4TlbY4udWWmaXH0[YQhWE:QMTD0doFve2GldHn2ZZRqd25? NELQdFMzOjNyNEK5Oi=>
201T MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7vNJc2KM7:TR?= NGTCVIs4OiCq MX;pcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghfmGwZHX0ZY5q[g>? M3XTOlIzOjV6NEe2
A549  MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTXOUDPxE1? M1jGZVczKGh? NUSwVoRUcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqII\hcoRmfGGwaXK= M3PVXlIzOjV6NEe2
MCF-7 M2DhXWZ2dmO2aX;uJGF{e2G7 MkLZNeKh|ryP NGHDXWQzPCCqwrC= NHj5bZhld3ewcnXneYxifGW|IFXSJIV5eHKnc4Ppc44hcW6mdXPl[EBjgSB2LV;IMXQhyqB? MV[yNlA1QTNzNh?=
HCC-1428 MW\GeY5kfGmxbjDBd5NigQ>? MnTMNeKh|ryP NFziSWszPCCqwrC= NUnUSFJl\G:5boLl[5Vt[XSnczDFVkBmgHC{ZYPzbY9vKGmwZIXj[YQh[nliND3PTE1VKMLi NHjxenQzOjB2OUOxOi=>
MDA-361 NWK5b|A3TnWwY4Tpc44hSXO|YYm= NF6xSnIyyqEQvF2= NWK2O|h7OjRiaNMg NIWzXZNld3ewcnXneYxifGW|IFXSJIV5eHKnc4Ppc44hcW6mdXPl[EBjgSB2LV;IMXQhyqB? MWWyNlA1QTNzNh?=
ZR75-1 MU\GeY5kfGmxbjDBd5NigQ>? MmfoNeKh|ryP MoqyNlQhcMLi Mnvy[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uJIlv\HWlZXSgZpkhPC2RSD3UJOKh MlTKNlIxPDl|MU[=
MCF-7 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfjTGwyyqEQvF2= M4W5V|UuOTBiZB?= NVPU[2s1e3WycILld5NmeyCHMj3pcoR2[2WmIHfyc5d1cCCrbnjpZol1cW:w NFv0U5IzOjB2OUOxOi=>
HCC-1428 MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHFO4IyyqEQvF2= M3jFfFUuOTBiZB?= NIDn[WZ{fXCycnXzd4V{KEV{LXnu[JVk\WRiZ4Lve5RpKGmwaHnibZRqd25? NXn5SmFkOjJyNEmzNVY>
MDA-361 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWexxsDPxE1? NHvlNoM2NTFyIHS= Mo\Ud5VxeHKnc4Pld{BGOi2rbnT1Z4VlKGe{b4f0bEBqdmirYnn0bY9v MoXkNlIxPDl|MU[=
ZR75-1 M1\aXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLaVHoyyqEQvF2= Mmm0OU0yOCCm MY\zeZBxemW|c3XzJGUzNWmwZIXj[YQh\3Kxd4ToJIlvcGmkaYTpc44> NVTWWIZ1OjJyNEmzNVY>
MCF-7/AC-1 Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS2[mIzOC1yLkKg{txO MWS2JIQ> MXLpcohq[mm2czDj[YxtKGe{b4f0bEBud2Snc4TsfS=> NGHGeYIzOjB2Mke5Ni=>
MCF7 M2XZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\kW|ExKML3TR?= NV\QT|RxPDhiaB?= NXe0SXJucW6mdXPld{Bk\WyuIHnubIljcXSrb36ge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IH\pZpJw[myjc4Tz M4H3UFIzODRzOEi3
MMQ MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPnPWFjOC14MkWgcm0> NFewXlY4OiCq NYPDZYR6eHKxZIXj[ZMhe3SjdHnzeIlk[WyueTDzbYdvcW[rY3HueEBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbtMg MUOyNlAyPTFyMR?=
MMQ NW[3PHBrTnWwY4Tpc44hSXO|YYm= M{TXOFAuPjJ3IH7N NY\TUo1PPzJiaB?= NUDjUIRLeHKxZIXj[ZMh[SC|dHH0bZN1cWOjbHz5JJNq\26rZnnjZY51NCCmb4PlMYRmeGWwZHXueEBz\WS3Y4Tpc44hcW5iUGLMJJNm[3KndHnvci=> M1TtWFIzODF3MUCx
MCF7 NYn3N3RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPVTm4xNTFizszN NGr1RnczPC1zMkCgbC=> NIT4TG5qdmirYnn0d{B1cGViZ4Lve5RpKG:oIF3DSlcuYUJvMdMg M{DNOlIyQDZ|MkW4
HepG2 MlnzRZBweHSxc3nzJGF{e2G7 M2LhRVAvOcLizszN MoPGNlQhcA>? MVPhZo9tcXOqZYOgeIhmKGW|dILv[4VvNWmwZIXj[YQhfXBvcnXneYxifGmxbjDv[kBieG:DSTDhcoQh[XCxTR?= NV3ZeYZUOjF6MU[yN|M>
MCF7–iFR3 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPLO2J7OjBvMUCwJI5O NVrqeGFIQTZiaB?= MVzlcohidmOnczDBVE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? NFrMR3czOTd7Mki4PS=>
MCF7S M1zqZmZ2dmO2aX;uJGF{e2G7 NEDXfIsyyqEQvF2= M3K3VVQ5KGh? Mki0[I94dnKnZ4XsZZRmeyCxdnXyZYxtKEWUzsGgdJJwfGWrbjDs[ZZmdHN? M2TXT|IyPTN|MUm1
MCF7 M3TSO2Z2dmO2aX;uJGF{e2G7 NYPQWlJZOcLizszN M{jxUVQ5KGh? NIfNe5Rld3ewcnXneYxifGW|IH;2[ZJidGxiRWNOtUBxem:2ZXnuJIxmfmWucx?= NWHDWpdWOjF3M{OxPVU>
MCF7S NXPFV2djTnWwY4Tpc44hSXO|YYm= M{Hrb|HDqM7:TR?= MnH6O{Bl M4jWXYF1fGWwdXH0[ZMhfHWvb4LzdIhmemViZn;ycYF1cW:wIHHu[EBxem:uaX\ldoF1cW:w NWPoO4g5OjF3M{OxPVU>
MCF7S MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDGNE42NzFizszN M2rpZlch\A>? NHzJZZFFVVOR NGXzR4pl\WO{ZXHz[ZMh[2WubDDlfJBidnOrb36= NF30TXgzOTV|M{G5OS=>
T47D  M335R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonIOEBvVQ>? NIDZWZU1OCCq NYTWNpJGe3WycILld5NmeyClZXzsJIdzd3e2aDDtc4RmemG2ZXz5 M{jkPFIyPDhyM{mx
BT474  NUfEU5BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLHOEBvVQ>? MlrqOFAhcA>? NEn6TJB{fXCycnXzd4V{KGOnbHyg[5Jwf3SqIH3v[IVz[XSnbIm= NFLjUlMzOTR6MEO5NS=>
T47D  MVTGeY5kfGmxbjDBd5NigQ>? M{jHOlExKG6P M1Hy[FQxKGh? Mn;o[I94dnKnZ4XsZZRmeyCHUt8xJJBzd3SnaX6= MkTKNlE1QDB|OUG=
BT474  M2q1[GZ2dmO2aX;uJGF{e2G7 NX;IbHlMOTBibl2= MXW0NEBp MWnkc5dvemWpdXzheIV{KEWUzsGgdJJwfGWrbh?= MUeyNVQ5ODN7MR?=
MCF7 NV7GTZB7TnWwY4Tpc44hSXO|YYm= NHzURVIyODBibl2= NEj0[m44KGR? MnH6doVlfWOnczDFVu6yKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> NE\oOWwzOTN7NkC5OC=>
T47D  NIfzWZFHfW6ldHnvckBCe3OjeR?= MUSxNFAhdk1? NG\VNlA4KGR? NUjQd2RSemWmdXPld{BGWs7zIHX4dJJme3Orb36gd4lodmmoaXPhcpRtgQ>? MkPoNlE{QTZyOUS=
BT474  M1rrPGZ2dmO2aX;uJGF{e2G7 NIrFZmMyODBibl2= M{jwUFch\A>? M3i5OpJm\HWlZYOgSXLPuSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk> MonxNlE{QTZyOUS=
MDAMB361 M{TETGZ2dmO2aX;uJGF{e2G7 NXuzOoM2OTByIH7N Mlz0O{Bl NF\jUXRz\WS3Y3XzJGVT|rFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 NFXVZVEzOTN7NkC5OC=>
MCF7 M3zHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXSyOlh6OC5yMT2xJO69VQ>? MmjIO{Bl NFu3cZJz\WS3Y3XzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= NHrhO5UzOTN7NkC5OC=>
T47D  Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\6VWExNjBzLUGg{txO NV7Ue5NCPyCm Mn7TdoVlfWOnczDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 NHfoW|czOTN7NkC5OC=>
BT474  NH3DT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGwMlAyNTFizszN NV\FV|lGPyCm NXjo[XB1emWmdXPld{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 MWiyNVM6PjB7NB?=
MDAMB361 NXzXfm9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TPfVAvODFvMTFOwG0> MWS3JIQ> NWXNNYVuemWmdXPld{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 M2XNTFIyOzl4MEm0
MCF7 MWPGeY5kfGmxbjDBd5NigQ>? NXfUcm1UOTByIH7N NIWzZWo4KGR? MkLkbY5lfWOnczDv[kBGemKEMzDhcoQhTXKkQkSgdoVk\XC2b4Kg[ZhxemW|c3nvckBidmRic3nncoFtdGmwZx?= M1j4elIyOzl4MEm0
T47D  NFfJOIRHfW6ldHnvckBCe3OjeR?= M3Pje|ExOCCwTR?= NX74SGxsPyCm MUTpcoR2[2W|IH;mJGVz[kJ|IHHu[EBGemKENDDy[YNmeHSxcjDlfJBz\XO|aX;uJIFv\CC|aXfuZYxtcW6p MkHxNlE{QTZyOUS=
BT474  Mn:4SpVv[3Srb36gRZN{[Xl? MlL3NVAxKG6P M3Xab|ch\A>? NXLJUHFEcW6mdXPld{Bw\iCHcnLCN{BidmRiRYLiRlQhemWlZYD0c5Ih\XiycnXzd4lwdiCjbnSgd4lodmGubHnu[y=> NYDNe3F[OjF|OU[wPVQ>
MDAMB361 M{HZT2Z2dmO2aX;uJGF{e2G7 M{DqeFExOCCwTR?= MVO3JIQ> Ml7DbY5lfWOnczDv[kBGemKEMzDhcoQhTXKkQkSgdoVk\XC2b4Kg[ZhxemW|c3nvckBidmRic3nncoFtdGmwZx?= M2mwXVIyOzl4MEm0
MCF7 NHPqb2xHfW6ldHnvckBCe3OjeR?= M{jFTVExKG6P NYXhNYhQQTZiaB?= MoTX[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uxsA> MV:yNVM4QDN|Mx?=
MDA-MB-231 MXjGeY5kfGmxbjDBd5NigQ>? M2fERlExKG6P NV\SbYpRQTZiaB?= MoXG[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uxsA> NUDrXJRFOjF|N{izN|M>
SK-BR-3 MkDTSpVv[3Srb36gRZN{[Xl? M3T2U|ExKG6P Mn\PPVYhcA>? Mn;Q[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uxsA> M2rMRVIyOzd6M{Oz
MCF-7 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSxNFAhdk1? MkT0O|IwQTZiaB?= NGLheIZk[XW|ZYOgZ4VtdCCleXPs[UBienKnc4S= MWmyNVI6QTh4Mh?=
MMQ MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELiUHUxNjByOD22NlUhdk1? NUDrWItLPzJiaB?= NHL4SpVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M4D4dVIxPzByN{W1
MMQ MoPOSpVv[3Srb36gRZN{[Xl? MV[wMlAxQC14MkWgcm0> MlPEO|IhcA>? NWH1[otKcW6qaXLpeJMhWFKOIIPlZ5JmfGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVSyNFcxODd3NR?=
MMQ M2P4W2Z2dmO2aX;uJGF{e2G7 NFX0bVExNjB2LU[yOUBvVQ>? NUnnPWdYPzJiaB?= Mlz4bY5pcWKrdIOgSXLPuSCneIDy[ZN{cW:w NFnYVXAzODdyMEe1OS=>
MMQ MVfGeY5kfGmxbjDBd5NigQ>? NYjXRlRWOC5yND22NlUhdk1? NIHiW4g4OiCq NFvFTo52eHKnZ4XsZZRmeyCWR1dOtlMh[W6mIGTHSu6zWkmLIHX4dJJme3Orb36= NWj6[FljOjB5MEC3OVU>

... Click to View More Cell Line Experimental Data

体内研究 Fulvestrant缺乏子宫活性,与雌二醇联用皮下注射给药未成熟的雌性大鼠,有效抑制雌二醇的子宫内活性,ED50 为0.06 mg/kg/day。5 mg Fulvestrant悬浮液皮下注射到MCF-7移植瘤中,完全抑制肿瘤生长。10 μM Fulvestrant也有效抑制BrlO人类乳腺癌移植瘤的生长。[1] Fulvestrant (10 mg/rat) 皮下注射到大鼠前列腺腹侧,降低雄激素受体的表达,ERK1/2磷酸化,和细胞增殖。[7]Fulvestrant作用于鸡胚绒毛尿囊膜还具有抗血管生成的作用效果。[8]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
+ 展开
  • Cell lines: MCF-7 乳腺癌细胞
  • Concentrations: 2.9 nM
  • Incubation Time: 5 天
  • Method: MCF-7细胞培养在多孔板中(24孔,按4 × 104密度为接种),孔中含基本必需培养基,培养基中包含酚红,胰岛素(10 μg/mL),和5%活性炭处理的胎牛血清,不含额外的雌二醇。接种2天后,在新鲜的培养基中加入Fulvestrant 和/或雌二醇。培养持续5天,且进一步改变培养基,通过在实验处理开始和结束测量全部细胞蛋白,且与只用乙醇(0.1%)处理的对照组进行比较后,测评生长状况。
    (Only for Reference)
动物实验:[6]
+ 展开
  • Animal Models: 携带人类乳腺癌移植瘤MCF-7的裸鼠
  • Formulation: 50 mg/mL 花生油
  • Dosages: 5 mg
  • Administration: 皮下注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (164.8 mM)
Ethanol 100 mg/mL warmed (164.8 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+95% Corn oil
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 606.77
化学式

C32H47F5O3S

CAS号 129453-61-8
稳定性 powder
in solvent
别名 ICI-182780, ZD 9238

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02340221 Active not recruiting Breast Cancer Hoffmann-La Roche April 9 2015 Phase 3
NCT01597388 Active not recruiting Advanced Metastatic Breast Cancer AstraZeneca May 8 2012 Phase 1
NCT00099437 Active not recruiting Breast Cancer AstraZeneca February 8 2005 Phase 3
NCT03377101 Withdrawn Estrogen Receptor Positive|HER2/Neu Negative|Progesterone Receptor Positive|Stage IV Breast Cancer AJCC v6 and v7 National Cancer Institute (NCI) August 7 2018 Phase 2
NCT01610284 Active not recruiting Breast Cancer Novartis Pharmaceuticals|Novartis August 7 2012 Phase 3
NCT02953860 Recruiting Breast Cancer University of Colorado Denver|United States Department of Defense July 6 2017 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is there any information for the half-life of fulvestrant (Cat No.S1191)?

  • 回答:

    S1191, is about 13.5 to 18.5 hours in vivo: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/. The half life of these compounds in cell culture might be different and we generally recommend replenishing with fresh drug every 24-48 hours.

Estrogen/progestogen Receptor Signaling Pathway Map

Estrogen/progestogen Receptor Inhibitors with Unique Features

相关Estrogen/progestogen Receptor产品

Tags: 购买Fulvestrant | Fulvestrant ic50 | Fulvestrant价格 | Fulvestrant DMSO溶解度 | 采购Fulvestrant | Fulvestrant生产 | Fulvestrant 小鼠 | Fulvestrant化学结构 | Fulvestrant分子量 | Fulvestrant molecular weight | Fulvestrant说明书 | Fulvestrant供应商 | Fulvestrant体内 | Fulvestrant细胞系 | Fulvestrant浓度 | Fulvestrant nmr | Fulvestrant核磁 | Fulvestrant半数抑制浓度 | Fulvestrant体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID